

AFFIRM-AHF Trial and subanalysis publications

AFFIRM-AHF

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

Citation: Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial [published correction appears in *Lancet*. 2021 Nov 27;398(10315):1964]. *Lancet*. 2020;396(10266):1895-1904.

Link to PDF: <https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2932339-4>

Health-Related Quality of Life

The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study

Citation: Jankowska EA, Kirwan BA, Kosiborod M, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study [published online ahead of print, 2021 Jun 3]. *Eur Heart J*. 2021;42(31):3011-3020.

Link to PDF: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370759/pdf/ehab234.pdf>

AFFIRM-AHF Subgroup Analysis Ischemic vs. Non-ischemic etiology

Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial

Citation: Metra M, Jankowska EA, Pagnesi M, et al. Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial [published online ahead of print, 2022 Jul 23]. *Eur J Heart Fail*. 2022;10.1002/ejhf.2630.

Link to PDF: <https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.2630>

Ferric Carboxymaltose Meta Analysis

Ferric carboxymaltose for the treatment of iron-deficient heart failure patients: a systematic review and meta-analysis

Citation: Khan MS, Usman MS, von Haehling S, Doehner W, Stewart Coats AJ. Ferric carboxymaltose for the treatment of iron-deficient heart failure patients: a systematic review and meta-analysis. *ESC Heart Fail*. 2020;7(6):3392-3400.

Link to PDF: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754952/pdf/EHF2-7-3392.pdf>

Guidelines

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure

Citation: Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. *J Card Fail.* 2022;28(5):e1-e167.

Link: <https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000001063?download=true>

2021 ESC Guidelines For The Diagnosis and Treatment of Acute and Chronic Heart Failure

Citation: McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. *Rev Esp Cardiol (Engl Ed).* 2022;75(6):523.

Link: <https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehab368/6358045>